Compare OGN & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | HYT |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | OGN | HYT |
|---|---|---|
| Price | $7.88 | $8.95 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.10 | N/A |
| AVG Volume (30 Days) | ★ 6.2M | 443.0K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | 1.01% | ★ 9.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $6,301,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.18 | $8.18 |
| 52 Week High | $17.23 | $9.91 |
| Indicator | OGN | HYT |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 53.48 |
| Support Level | $7.74 | $8.79 |
| Resistance Level | $8.48 | $8.93 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 6.59 | 78.57 |
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income and capital appreciation. The trust's secondary investment objective is to provide shareholders with capital appreciation. It seeks to achieve its objectives by investing in a diversified portfolio of fixed-income securities.